Report Detail
Global Non-viral Vectors Gene Therapy Market Growth (Status and Outlook) 2022-2028
- RnM4475163 |
- 02 August, 2022 |
- Global |
- 103 Pages |
- LPI(LP Information) |
- Medical Industry
The global market for Non-viral Vectors Gene Therapy is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Non-viral Vectors Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Non-viral Vectors Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Non-viral Vectors Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Non-viral Vectors Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Non-viral Vectors Gene Therapy players cover Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen and Novartis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Non-viral Vectors Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Non-viral Vectors Gene Therapy market, with both quantitative and qualitative data, to help readers understand how the Non-viral Vectors Gene Therapy market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Non-viral Vectors Gene Therapy market and forecasts the market size by Type (Oligonucleotides and Other Non-viral Vectors,), by Application (In Vivo and Ex Vivo.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Oligonucleotides
Other Non-viral Vectors
Segmentation by application
In Vivo
Ex Vivo
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Chapter Introduction
Chapter 1: Scope of Non-viral Vectors Gene Therapy, Research Methodology, etc.
Chapter 2: Executive Summary, global Non-viral Vectors Gene Therapy market size and CAGR, Non-viral Vectors Gene Therapy market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Non-viral Vectors Gene Therapy revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Non-viral Vectors Gene Therapy revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Non-viral Vectors Gene Therapy market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Non-viral Vectors Gene Therapy Market Size 2017-2028
- 2.1.2 Non-viral Vectors Gene Therapy Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Non-viral Vectors Gene Therapy Segment by Type
- 2.2.1 Oligonucleotides
- 2.2.2 Other Non-viral Vectors
- 2.3 Non-viral Vectors Gene Therapy Market Size by Type
- 2.3.1 Non-viral Vectors Gene Therapy Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Non-viral Vectors Gene Therapy Market Size Market Share by Type (2017-2022)
- 2.4 Non-viral Vectors Gene Therapy Segment by Application
- 2.4.1 In Vivo
- 2.4.2 Ex Vivo
- 2.5 Non-viral Vectors Gene Therapy Market Size by Application
- 2.5.1 Non-viral Vectors Gene Therapy Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Non-viral Vectors Gene Therapy Market Size Market Share by Application (2017-2022)
3 Non-viral Vectors Gene Therapy Market Size by Player
- 3.1 Non-viral Vectors Gene Therapy Market Size Market Share by Players
- 3.1.1 Global Non-viral Vectors Gene Therapy Revenue by Players (2020-2022)
- 3.1.2 Global Non-viral Vectors Gene Therapy Revenue Market Share by Players (2020-2022)
- 3.2 Global Non-viral Vectors Gene Therapy Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Non-viral Vectors Gene Therapy by Regions
- 4.1 Non-viral Vectors Gene Therapy Market Size by Regions (2017-2022)
- 4.2 Americas Non-viral Vectors Gene Therapy Market Size Growth (2017-2022)
- 4.3 APAC Non-viral Vectors Gene Therapy Market Size Growth (2017-2022)
- 4.4 Europe Non-viral Vectors Gene Therapy Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Non-viral Vectors Gene Therapy Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Non-viral Vectors Gene Therapy Market Size by Country (2017-2022)
- 5.2 Americas Non-viral Vectors Gene Therapy Market Size by Type (2017-2022)
- 5.3 Americas Non-viral Vectors Gene Therapy Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Non-viral Vectors Gene Therapy Market Size by Region (2017-2022)
- 6.2 APAC Non-viral Vectors Gene Therapy Market Size by Type (2017-2022)
- 6.3 APAC Non-viral Vectors Gene Therapy Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Non-viral Vectors Gene Therapy by Country (2017-2022)
- 7.2 Europe Non-viral Vectors Gene Therapy Market Size by Type (2017-2022)
- 7.3 Europe Non-viral Vectors Gene Therapy Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Non-viral Vectors Gene Therapy by Region (2017-2022)
- 8.2 Middle East & Africa Non-viral Vectors Gene Therapy Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Non-viral Vectors Gene Therapy Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Non-viral Vectors Gene Therapy Market Forecast
- 10.1 Global Non-viral Vectors Gene Therapy Forecast by Regions (2023-2028)
- 10.1.1 Global Non-viral Vectors Gene Therapy Forecast by Regions (2023-2028)
- 10.1.2 Americas Non-viral Vectors Gene Therapy Forecast
- 10.1.3 APAC Non-viral Vectors Gene Therapy Forecast
- 10.1.4 Europe Non-viral Vectors Gene Therapy Forecast
- 10.1.5 Middle East & Africa Non-viral Vectors Gene Therapy Forecast
- 10.2 Americas Non-viral Vectors Gene Therapy Forecast by Country (2023-2028)
- 10.2.1 United States Non-viral Vectors Gene Therapy Market Forecast
- 10.2.2 Canada Non-viral Vectors Gene Therapy Market Forecast
- 10.2.3 Mexico Non-viral Vectors Gene Therapy Market Forecast
- 10.2.4 Brazil Non-viral Vectors Gene Therapy Market Forecast
- 10.3 APAC Non-viral Vectors Gene Therapy Forecast by Region (2023-2028)
- 10.3.1 China Non-viral Vectors Gene Therapy Market Forecast
- 10.3.2 Japan Non-viral Vectors Gene Therapy Market Forecast
- 10.3.3 Korea Non-viral Vectors Gene Therapy Market Forecast
- 10.3.4 Southeast Asia Non-viral Vectors Gene Therapy Market Forecast
- 10.3.5 India Non-viral Vectors Gene Therapy Market Forecast
- 10.3.6 Australia Non-viral Vectors Gene Therapy Market Forecast
- 10.4 Europe Non-viral Vectors Gene Therapy Forecast by Country (2023-2028)
- 10.4.1 Germany Non-viral Vectors Gene Therapy Market Forecast
- 10.4.2 France Non-viral Vectors Gene Therapy Market Forecast
- 10.4.3 UK Non-viral Vectors Gene Therapy Market Forecast
- 10.4.4 Italy Non-viral Vectors Gene Therapy Market Forecast
- 10.4.5 Russia Non-viral Vectors Gene Therapy Market Forecast
- 10.5 Middle East & Africa Non-viral Vectors Gene Therapy Forecast by Region (2023-2028)
- 10.5.1 Egypt Non-viral Vectors Gene Therapy Market Forecast
- 10.5.2 South Africa Non-viral Vectors Gene Therapy Market Forecast
- 10.5.3 Israel Non-viral Vectors Gene Therapy Market Forecast
- 10.5.4 Turkey Non-viral Vectors Gene Therapy Market Forecast
- 10.5.5 GCC Countries Non-viral Vectors Gene Therapy Market Forecast
- 10.6 Global Non-viral Vectors Gene Therapy Forecast by Type (2023-2028)
- 10.7 Global Non-viral Vectors Gene Therapy Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Biogen
- 11.1.1 Biogen Company Information
- 11.1.2 Biogen Non-viral Vectors Gene Therapy Product Offered
- 11.1.3 Biogen Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Biogen Main Business Overview
- 11.1.5 Biogen Latest Developments
- 11.2 Sarepta Therapeutics
- 11.2.1 Sarepta Therapeutics Company Information
- 11.2.2 Sarepta Therapeutics Non-viral Vectors Gene Therapy Product Offered
- 11.2.3 Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Sarepta Therapeutics Main Business Overview
- 11.2.5 Sarepta Therapeutics Latest Developments
- 11.3 Gilead Sciences
- 11.3.1 Gilead Sciences Company Information
- 11.3.2 Gilead Sciences Non-viral Vectors Gene Therapy Product Offered
- 11.3.3 Gilead Sciences Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Gilead Sciences Main Business Overview
- 11.3.5 Gilead Sciences Latest Developments
- 11.4 Amgen
- 11.4.1 Amgen Company Information
- 11.4.2 Amgen Non-viral Vectors Gene Therapy Product Offered
- 11.4.3 Amgen Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Amgen Main Business Overview
- 11.4.5 Amgen Latest Developments
- 11.5 Novartis
- 11.5.1 Novartis Company Information
- 11.5.2 Novartis Non-viral Vectors Gene Therapy Product Offered
- 11.5.3 Novartis Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Novartis Main Business Overview
- 11.5.5 Novartis Latest Developments
- 11.6 Orchard Therapeutics
- 11.6.1 Orchard Therapeutics Company Information
- 11.6.2 Orchard Therapeutics Non-viral Vectors Gene Therapy Product Offered
- 11.6.3 Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Orchard Therapeutics Main Business Overview
- 11.6.5 Orchard Therapeutics Latest Developments
- 11.7 Spark Therapeutics
- 11.7.1 Spark Therapeutics Company Information
- 11.7.2 Spark Therapeutics Non-viral Vectors Gene Therapy Product Offered
- 11.7.3 Spark Therapeutics Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Spark Therapeutics Main Business Overview
- 11.7.5 Spark Therapeutics Latest Developments
- 11.8 Agc Biologics
- 11.8.1 Agc Biologics Company Information
- 11.8.2 Agc Biologics Non-viral Vectors Gene Therapy Product Offered
- 11.8.3 Agc Biologics Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 Agc Biologics Main Business Overview
- 11.8.5 Agc Biologics Latest Developments
- 11.9 Anges
- 11.9.1 Anges Company Information
- 11.9.2 Anges Non-viral Vectors Gene Therapy Product Offered
- 11.9.3 Anges Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 Anges Main Business Overview
- 11.9.5 Anges Latest Developments
- 11.10 Bluebird Bio
- 11.10.1 Bluebird Bio Company Information
- 11.10.2 Bluebird Bio Non-viral Vectors Gene Therapy Product Offered
- 11.10.3 Bluebird Bio Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 Bluebird Bio Main Business Overview
- 11.10.5 Bluebird Bio Latest Developments
- 11.11 Jazz Pharmaceuticals
- 11.11.1 Jazz Pharmaceuticals Company Information
- 11.11.2 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Product Offered
- 11.11.3 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.11.4 Jazz Pharmaceuticals Main Business Overview
- 11.11.5 Jazz Pharmaceuticals Latest Developments
- 11.12 Dynavax Technologies
- 11.12.1 Dynavax Technologies Company Information
- 11.12.2 Dynavax Technologies Non-viral Vectors Gene Therapy Product Offered
- 11.12.3 Dynavax Technologies Non-viral Vectors Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)
- 11.12.4 Dynavax Technologies Main Business Overview
- 11.12.5 Dynavax Technologies Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Non-viral Vectors Gene Therapy. Industry analysis & Market Report on Non-viral Vectors Gene Therapy is a syndicated market report, published as Global Non-viral Vectors Gene Therapy Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Non-viral Vectors Gene Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
